DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis
NASDAQ:DVAX - Nasdaq - US2681582019 - Common Stock - Currency: USD
Taking everything into account, DVAX scores 5 out of 10 in our fundamental rating. DVAX was compared to 558 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year DVAX was profitable.
DVAX had a positive operating cash flow in the past year.
In multiple years DVAX reported negative net income over the last 5 years.
DVAX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -6.35%, DVAX belongs to the best of the industry, outperforming 86.92% of the companies in the same industry.
Looking at the Return On Equity, with a value of -11.31%, DVAX belongs to the top of the industry, outperforming 87.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -11.31% | ||
| ROIC | N/A |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of DVAX has declined.
The Gross Margin of DVAX (82.27%) is better than 86.38% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DVAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
Compared to 5 years ago, DVAX has more shares outstanding
DVAX has a worse debt/assets ratio than last year.
2.2 Solvency
DVAX has an Altman-Z score of 1.49. This is a bad value and indicates that DVAX is not financially healthy and even has some risk of bankruptcy.
DVAX has a Altman-Z score of 1.49. This is in the better half of the industry: DVAX outperforms 69.18% of its industry peers.
DVAX has a debt to FCF ratio of 4.82. This is a neutral value as DVAX would need 4.82 years to pay back of all of its debts.
DVAX's Debt to FCF ratio of 4.82 is amongst the best of the industry. DVAX outperforms 93.37% of its industry peers.
DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.49, DVAX is not doing good in the industry: 74.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.82 | ||
| Altman-Z | 1.49 |
ROIC/WACCN/A
WACC9.08%
2.3 Liquidity
A Current Ratio of 11.93 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a better Current ratio (11.93) than 82.80% of its industry peers.
A Quick Ratio of 10.84 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a better Quick ratio (10.84) than 80.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.93 | ||
| Quick Ratio | 10.84 |
3. Growth
3.1 Past
DVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 325.00%, which is quite impressive.
The earnings per share for DVAX have been decreasing by -19.10% on average. This is quite bad
Looking at the last year, DVAX shows a very strong growth in Revenue. The Revenue has grown by 24.79%.
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)325%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%107.14%
Revenue 1Y (TTM)24.79%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%34.21%
3.2 Future
Based on estimates for the next years, DVAX will show a very strong growth in Earnings Per Share. The EPS will grow by 61.35% on average per year.
DVAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.89% yearly.
EPS Next Y-32.75%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y18.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DVAX is valuated quite expensively with a Price/Earnings ratio of 38.04.
93.37% of the companies in the same industry are more expensive than DVAX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.43. DVAX is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 18.24, DVAX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaply inside the industry as 93.01% of the companies are valued more expensively.
DVAX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.17, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.04 | ||
| Fwd PE | 18.24 |
4.2 Price Multiples
DVAX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DVAX is cheaper than 94.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.98 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DVAX's earnings are expected to grow with 61.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.55%
EPS Next 3Y61.35%
5. Dividend
5.1 Amount
DVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.89
-0.12 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.49%
Inst Owner Change-1.55%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap1.19B
Analysts80
Price Target24.48 (147.52%)
Short Float %12.85%
Short Ratio6.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-34.97%
Min EPS beat(2)-86.66%
Max EPS beat(2)16.71%
EPS beat(4)3
Avg EPS beat(4)-11.24%
Min EPS beat(4)-86.66%
Max EPS beat(4)21.41%
EPS beat(8)6
Avg EPS beat(8)91.96%
EPS beat(12)9
Avg EPS beat(12)84.56%
EPS beat(16)10
Avg EPS beat(16)32.97%
Revenue beat(2)0
Avg Revenue beat(2)-4.07%
Min Revenue beat(2)-4.19%
Max Revenue beat(2)-3.96%
Revenue beat(4)0
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)-3.96%
Revenue beat(8)3
Avg Revenue beat(8)1.24%
Revenue beat(12)7
Avg Revenue beat(12)8.29%
Revenue beat(16)9
Avg Revenue beat(16)10.65%
PT rev (1m)0%
PT rev (3m)1.69%
EPS NQ rev (1m)-9.54%
EPS NQ rev (3m)-16.43%
EPS NY rev (1m)-64.81%
EPS NY rev (3m)-53.94%
Revenue NQ rev (1m)2.09%
Revenue NQ rev (3m)-1.05%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)-0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.04 | ||
| Fwd PE | 18.24 | ||
| P/S | 4.03 | ||
| P/FCF | 21.98 | ||
| P/OCF | 18.69 | ||
| P/B | 2.24 | ||
| P/tB | 2.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.26
EY2.63%
EPS(NY)0.54
Fwd EY5.48%
FCF(TTM)0.45
FCFY4.55%
OCF(TTM)0.53
OCFY5.35%
SpS2.45
BVpS4.42
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -11.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.27% | ||
| FCFM | 18.34% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.82 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 117.09% | ||
| Cap/Sales | 3.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.93 | ||
| Quick Ratio | 10.84 | ||
| Altman-Z | 1.49 |
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)325%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%107.14%
EPS Next Y-32.75%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue 1Y (TTM)24.79%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%34.21%
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y18.89%
EBIT growth 1Y56.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year356.6%
EBIT Next 3Y104.13%
EBIT Next 5YN/A
FCF growth 1Y-59.6%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-54.83%
OCF growth 3Y-41.69%
OCF growth 5YN/A